ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Xiaoting Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1329-9761; OpenAlex author ID A5050437390, A5121334173. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 14

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 4

Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report. Co-author DOI 10.21037/cco-2025-aw-132 ↗
The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer. Co-author DOI 10.1186/s12876-025-04119-z ↗
Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1186/s12885-025-13799-5 ↗
Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. Co-author DOI 10.3389/fonc.2023.1151178 ↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kai Ou · 2 shared papers, 2023–2025 · strength 0.44
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
- Paper Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case r… DOI 10.3389/fonc.2023.1151178 ↗
Yuejuan Cheng · 1 shared paper, 2026 · strength 0.33
- Paper Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case repor… DOI 10.21037/cco-2025-aw-132 ↗
Yi Ba · 1 shared paper, 2026 · strength 0.33
- Paper Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case repor… DOI 10.21037/cco-2025-aw-132 ↗
Songbing Qin · 1 shared paper, 2025 · strength 0.26
- Paper The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer. DOI 10.1186/s12876-025-04119-z ↗
Jinzhou Zhu · 1 shared paper, 2025 · strength 0.26
- Paper The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer. DOI 10.1186/s12876-025-04119-z ↗
Jiaxi Lin · 1 shared paper, 2025 · strength 0.26
- Paper The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer. DOI 10.1186/s12876-025-04119-z ↗
Jinli Li · 1 shared paper, 2025 · strength 0.26
- Paper The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer. DOI 10.1186/s12876-025-04119-z ↗
Zheng Dou · 1 shared paper, 2025 · strength 0.26
- Paper The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer. DOI 10.1186/s12876-025-04119-z ↗
Biyang Cao · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Wen Zhang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Letian Zhang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Wenwei Yang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Lin Yang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Lin Yang · 1 shared paper, 2023 · strength 0.22
- Paper Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case r… DOI 10.3389/fonc.2023.1151178 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.